AlphAIAlphAI — Financial news for AI agents
globes.co.ilOCT 151 min read$WSE

Former Nice CEO Barak Eilam to chair UK fintech co

Barak Eilam, former CEO of Nice (NICE), will join Wise Group (WISE, WSE) as a director and future chairman, replacing David Wells. Wise, a London-based fintech firm with a $11.7B market cap, provides money transfer services. Eilam has nearly 30 years of tech experience and previously led Nice for a decade, earning $147M in total compensation.

Original reporting
globes.co.il
Published Oct 15, 2026, 9:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 10:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Former Nice CEO Barak Eilam to chair UK fintech co — source image
Source · globes.co.il
Decision brief

The 30-second read

$WSEBullishMed
01

Why it matters

The leadership change could improve Wise's strategic execution and investor perception, possibly supporting the stock.

02

Market read

Executive appointment news for a mid‑cap fintech; modest trading relevance.

03

What to watch

Potential integration challenges or cultural fit issues could temper optimism.

Relevance 6/10Novelty 6/10Timing: immediate

Background

Barak Eilam, former CEO of Nice (NASDAQ:NICE), is joining Wise Group's board and will become chairman, replacing David Wells.

Company-level read

Ticker impact

$WSEBullishHigh confidence
Context

Wise Group announced former Nice CEO Barak Eilam will join its board and become chairman.

Expected impact

likely upward pressure as market prices in leadership credibility

Evidence & confidence

Eilam's track record at Nice suggests strong operational expertise; investors often reward such appointments.

Market effects

Sector

May boost confidence in fintech and cross‑border payments sector.

Regional

Positive signal for UK‑based fintechs listed in the US.

Global

Limited to Wise and peers; no broad market shift expected.

Counterpoint

What could challenge this read

Board changes rarely move price; market may already price in leadership quality.

Key entities

  • company
    Wise Group plc

    London‑based fintech provider of money‑transfer services, listed on NASDAQ as WSE.

  • person
    Barak Eilam

    Former CEO of Nice, now appointed chairman of Wise.

Read at source← All news

Related articles

OCT 13
$WSEMed

UBS raises Wise price target 12% to 1,300p ahead of results

UBS raised its price target for Wise Group PLC (WISE, WSE) to 1,300p, up 12% from 1,160p, citing expected higher interest rates. The new target is 41.6% above Wise's recent closing price of 918p. UBS forecasts earnings per share of US$0.82 for 2028, driven by higher interest rates. Wise is set to report Q2 results on Thursday, with UBS expecting pre-tax profit margins above guidance.

finance.yahoo.com1 min
JUL 21
$WSEMed

Wise Group plc launches share buyback program

Wise Group plc (Nasdaq: WSE, LSE: WISE) confirmed the start of a previously announced share buyback program. It hired Goldman Sachs International to repurchase Class A ordinary shares for up to £405 million (about $540 million), starting July 21, 2026 and ending by March 31, 2027. About 40% goes to an Employee Share Trust and 60% to treasury.

investegate.co.uk2 min
JUL 17
$WSEMedAI 8/10

Wise Q1 FY27 Trading Update

Wise Group plc reported Q1 FY27 results for the quarter ended June 30, 2026. Active customers rose 21% YoY to 11.9 million, cross-border volume increased 26% to $69.3B, and net revenue grew 25% to $714.0M. Customer holdings rose 31% to $41.2B. The cross-border take rate fell 2 bps to 50 bps. Wise reiterated FY27 guidance.

investegate.co.uk4 min
OCT 15
$IRDMedAI 9/10

Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026

Opus Genetics, Inc. (IRD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026 OPGx-BEST1 showed improved retinal sensitivity in 75% of evaluable participants in the initial low-dose Cohort 1 of the Company’s Phase 1/2 clinica

SEC EDGAR 8-K2 min